Antimicrobial Agents 101. SWACM 2011 Christopher Doern, Ph.D., D(ABMM)

Similar documents
Antimicrobial Susceptibility Testing: Advanced Course

2015 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Approach to pediatric Antibiotics

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Principles of Antibiotics Use & Spectrum of Some

Advanced Practice Education Associates. Antibiotics

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

European Committee on Antimicrobial Susceptibility Testing

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Intrinsic, implied and default resistance

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Antimicrobial susceptibility

RCH antibiotic susceptibility data

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

EUCAST recommended strains for internal quality control

CONTAGIOUS COMMENTS Department of Epidemiology

Aminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.

European Committee on Antimicrobial Susceptibility Testing

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Concise Antibiogram Toolkit Background

GENERAL NOTES: 2016 site of infection type of organism location of the patient

CONTAGIOUS COMMENTS Department of Epidemiology

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

What s new in EUCAST methods?

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Mechanism of antibiotic resistance

Other Beta - lactam Antibiotics

Understanding the Hospital Antibiogram

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

Antimicrobial Susceptibility Testing: The Basics

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

ß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

What s next in the antibiotic pipeline?

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

Antimicrobial Susceptibility Patterns

January 2014 Vol. 34 No. 1

CONTAGIOUS COMMENTS Department of Epidemiology

Antimicrobials. Antimicrobials

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

number Done by Corrected by Doctor Dr Hamed Al-Zoubi

Protein Synthesis Inhibitors

Antimicrobial Therapy

EDUCATIONAL COMMENTARY A PRIMER IN ANTIBIOTICS FOR THE LABORATORY PROFESSIONAL

Antibiotic Updates: Part II

Management of Antibiotic Resistant Pathogens

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

British Society for Antimicrobial Chemotherapy

Antibiotics 1. Lecture 8

Antibiotics: What You Need to Know in 2017

Fundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3

British Society for Antimicrobial Chemotherapy

EUCAST-and CLSI potency NEO-SENSITABS

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

Infectious Disease: Drug Resistance Pattern in New Mexico

Rational management of community acquired infections

56 Clinical and Laboratory Standards Institute. All rights reserved.

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

Antimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Antimicrobial Resistance Trends in the Province of British Columbia

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Antimicrobial Susceptibility Summary 2011

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

Antimicrobial Resistance and Prescribing

Antimicrobials Agents Review

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.

Antibiotics (2): - Before you start: this lecture has a lot of names and things get entangled together, but I

10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification

Drug Class Prior Authorization Criteria Intravenous Antibiotics

January 2014 Vol. 34 No. 1

Cipro for gram positive cocci in urine

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

M45: INFREQUENTLY ISOLATED OR FASTIDIOUS BACTERIA

Transcription:

Antimicrobial Agents 101 SWACM 2011 Christopher Doern, Ph.D., D(ABMM)

β -Lactams Penicillins Cephalosporins Carbapenems Monobactams β -Lactamase Inhibitors Clavulanate Amox/Clav Ticar/Clav Sulbactam Amp/Sulb Tazobactam Pip/Tazo Back to Basics: Cell Wall Acting Antibiotics Bactericidal Inhibit cell wall synthesis by blocking transpeptidase (Penicillin binding protein or PBP) activity. Weak antibacterial activity Potent inhibitors of some β-lactamases

Beta-lactam Video http://www.youtube.com/watch_popup?v=qbdynrhdwcq&vq=medium

Beta-Lactam Spectrum of Activity Active* Aerobic and anaerobic Gram positive cocci and bacilli Aerobic and anaerobic Gram negative bacilli Beta-Lactamase inhibitors used to inhibit beta-lactamases produced by anaerobes Other organisms Pasteurella Streptobacillus Treponema pallidum Erysypelothrix Inactive Carbapenemase producing Gram negative bacilli Ampicillin resistant Enterococci Mycoplasma Stenotrophomonas maltophilia MRSA *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Common Clinical Indications for Beta-Lactams Penicillin or Ampicillin Severe Enterococcal infection (plus gentamicin for synergy) GAS and GBS Actinomyces Syphillis Beta-lactam + inhibitor Bite wounds Infections expected to include anaerobes Uncomplicated UTI GAS pharyngitis Otitis media Pip/Tazo P. aeruginosa Kucers : The Use of Antibiotics, 6 th Edition Cefazolin and Cefalothin* (1 st gen cephs) MSSA infection *Itself rarely used but predicts susceptibility to oral 1 st gen cephs Cefotaxime and Ceftriaxone Empiric treatment for meningitis Ampicillin added to those <2 months if Listeria suspected Pneumococcal infection N. gonorrhoeae and meningitidis Serious Gram negative infection Ceftazidime Empiric treatment of fever and neutropenia P. aeruginosa infection Carbapenems Serious, resistant Gram negative infections Medical Letter, Inc. June 2010

Back to Basics: Other Cell Wall Acting Antibiotics Glycopeptides Vancomycin Teicoplanin Lipopeptides Daptomycin Polymyxins Colistin Inhibits assembly of peptidoglycan precursors (murein) Slowly bactericidal Binds to cell membrane and disrupts bacterial cell membrane potential Rapidly bactericidal Penetrate and disrupt cell membranes Rapidly bactericidal

Spectrum of Activity Active* Glycopeptides and Lipopeptides Gram positive cocci and bacilli Inactive Glycopeptides and Lipopeptides Gram negatives Polymyxins Gram negative Polymyxins Gram positives Anaerobes Burkholderia Proteus Serratia Providencia *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Common Clinical Indications for Use Vancomycin Empiric coverage for Gram positive infection MRSA Recurrent C. difficile infection Daptomycin VRE MRSA non-respiratory Colistin Hospital acquired ventilator associated pneumonia MDR Acinetobacter MDR Gram negatives Can be nebulized for respiratory infections Medical Letter, Inc. June 2010

Back to Basics: Protein Synthesis Inhibitors Oxazolidinones Linezolid Tetracyclines and Chloramphenicol Doxy-, Mino-, Tetra-, Tigecycline Chloramphenicol www.accessmedicine.net http://pharmaxchange.info/press/wp-content/uploads/2011/06/oxazolidinone-115x115.png

Back to Basics: Protein Synthesis Inhibitors MLSb Antibiotics Macrolides Erythromycin, Clarithromycin and Azithromycin Lincosamides Clindamycin Streptogramins www.accessmedicine.net Synercid Bind 50S subunit and inhibit peptide chain elongation Bind 50S and inhibit both addition of peptides and chain elongation

Macrolide Video http://www.youtube.com/watch_popup?v=oc21vlftsjo&vq=medium

Spectrum of Activity Linezolid Gram positives Nocardia Mycobacteria Active* Tetracyclines and Chloramphenicol Aerobic and anaerobic Gram positives Aerobic and anaerobic Gram negatives Spirochetes Rickettsiae, chlamydiae, mycoplasmas and protozoans Inactive Linezolid Gram negatives Mycoplasmas and ureaplasmas *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Spectrum of Activity Macrolides Active* Aerobic and anaerobic Gram positives and Gram negatives Treponemes, mycoplasmas, Chlamydia and rickettsiae Lincosamides Aerobic and anaerobic Gram positives and Gram negatives Streptogramins Aerobic and anaerobic Gram positives Some Gram negatives Inactive Lincosamides Enterobacteriaceae Streptogramins Enterococcus faecalis Enterobacteriaceae Pseudomonas aeruginosa Acinetobacter *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Common Clinical Indications for Use Azithromycin Legionella Chlamydia Acute otitis media Acute exacerbations of chronic bronchitis CAP in low MDR risk patients Pertusiss Shigella in children Immunomodulating agent in CF Linezolid MRSA Skin and soft-tissue infection Pneumonia VRE Clindamycin (not exhaustive) S. aureus infections (MRSA and MSSA) Skin and connective tissue infections Bites, acne, cellulitis, necrotizing fasciitis to name a few Bone and joint infections Bacterial pneumonia Abscesses Skin, head and neck, retro and parapharyngeal Toxin producing infections caused by Gram positives Doxycycline Tick-borne disease Ehrlichia, Lyme disease, Typhus, RMSF Chlamydia Pelvic inflammatory disease Bartonella Prophylaxis for agents of bioterrorism Kucers : The Use of Antibiotics, 6 th Edition Medical Letter, Inc. June 2010

Back to Basics: Protein Synthesis Inhibitors Aminoglycosides Gentamicin, Amikacin, Tobramycin, Spectinomycin and many more Interfere with proofreading mechanism resulting in premature termination Interfere with protein synthesis by blocking ribosomal tranlocation Can disrupt integrity of cell membrane Some bind to 50S and other 30S subunit

Aminoglycoside Spectrum of Activity Active* Aerobic Gram positives and Gram negatives Mycobacteria Inactive Anaerobes MRSA S. pneumoniae Stenotrophomonas maltophilia Burkholderia cepacia *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Common Clinical Indications for Use Aminoglycosides Synergy with beta-lactam Viridans group streptococci (Gentamicin) Listeria (Gentamicin) Pseudomonas aeruginosa (Pip/Tazo) Enterococcus spp. (high level) Tularemia, plague and Brucella Complicated UTI Serious Gram negative infections Kucers : The Use of Antibiotics, 6 th Edition Medical Letter, Inc. June 2010

Back to Basics: DNA Synthesis Inhibitors Quinolones and Fluorquinolones Numerous Nalidixic acid, Ciprofloxacin, Levofloxacin, Gatifloxacin and Moxifloxacin

Quinolone Video http://www.youtube.com/watch_popup?v=ikkz_gxaoxi&vq=medium

Quinolone Spectrum of Activity Active* Inactive Aerobic Gram negatives and Gram positives Anaerobic Gram negatives and Gram positives Mycobacteria Mycoplasma, Chlamydia and Treponema *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Back to Basics: RNA Synthesis Inhibitors Rifamycins Rifampicin (rifampin), rifabutin, rifapentine Interferes with DNAdependent RNA polymerase to inhibit RNA synthesis Sassetti and Rubin. 2007. Nat. Med.

Rifamycin Spectrum of Activity Active* Inactive Mycobacterium tuberculosis Non-tuberculous mycobacteria Gram positive cocci Gram negative bacilli Some anaerobes Neisseria meningitidis (oropharyngeal clearance) Other organisms Chlamydia Bartonella Legionella H. pylori Ehrlichia Brucella *In many cases susceptibility testing necessary to confirm activity of specific class of beta-lactam against individual isolates.

Common Clinical Indications for Use Rifampin Haemophilus influenzae type B and N. meningitis contact prophylaxis TB, MAI and other mycobacteria Combination therapy Serious staphylococcal infection Brucella infections Bartonella infection Coxiella infection Medical Letter, Inc. June 2010

Recommendations for Top 6 Infections 1. Skin and soft tissue Uncomplicated: MRSA, MSSA, Group A Streptococcus Recommendation: MRSA - Drainage alone, bactrim, doxy, clinda or linezolid Non-MRSA 1 st gen ceph, if hospitalized nafcillin or cefazolin, clinda or vanc. Complicated: Above plus Gram negative bacilli (E. coli and P. aeruginosa) Recommendation: Vanc, dapto and linezolid If polymicrobic w/out MRSA amp/sulb, pip/tazo, carbapenem (not erta) If GAS or Clostridium likely clinda plus penicillin

Recommendations for Top 6 Infections 2. Bone and Joint Acute Osteomyelitis: Common S. aureus, Group A Streptococcus Rare Salmonella, E. coli, PA Recommendation: MRSA Empiric = vanc, Confirmed = Dapto, Vanc or Lzd GC = Ceftriaxone Streptococci = Pen or Ceftriaxone Chronic Osteomyelitis: Recommendation : SURGICAL DEBRIDEMENT followed by bactrim, metronidazole, linezolid or moxifloxacin Septic arthritis: S. aureus, Group A Streptococcus, Pneumococcus, GC Prosthetic joint Coag. Neg Staph., S. aureus Recommendation: MRSA Empiric = vanc, Confirmed = Dapto, Vanc or Lzd GC = Ceftriaxone Streptococci = Pen or Ceftriaxone

Recommendations for Top 6 Infections 3. Meningitis Adults and Children: Common Pneumococcus and N. meningitidis Rare HIB Recommendation: Ceftriaxone and vancomycin for resistant pneumococcu Neonates and Elderly: Group B Streptococcus, Listeria, Enterobacteriaceae Recommendation : Ampcillin plus ceftriaxone +/- gentamicin

Recommendations for Top 6 Infections 4. Upper Respiratory Tract Acute Sinusitis: Common Pneumococcus, H. influenzae, M. catarrhalis Recommendation: amoxicillin or amox/clav, cefuroxime, cefpodoxime or levofloxacin. Doxy or Bactrim for pen-allergic Exacerbations of sinusitis: Same as above plus Pseudomonas in COPD Recommendation : Same as above plus cipro or ceftazidime for Pseudomonas Pharyngitis: Group A Streptococci Recommendation : Penicillin, amoxicillin or macrolide

Recommendations for Top 6 Infections 5. Pneumonia CAP: Common Pneumococcus, S. aureus, H. influenzaeatypicals (Mycoplasma, Chlamydophila, Legionella) Recommendation: AMBULATORY: Azithromycin or Doxycycline or Fluoroquinolone HOSPITALIZED: Ceftriaxone plus macrolide or fluoroquinolone IF SEVERE MRSA: Vanc, bactrim, linezolid Hospital Acquired or VAP: GNR s (Enterics, P. aeruginosa, Acinetobacter), S. aureus Recommendation : If no risk factors for MDR = ceftriaxone, levo or moxi, pip/tazo If risk for MDR = pip/tazo, cefepime, carbapenem (not erta), vancomycin, linezolid, colistin or tigecycline (when options limited)

Recommendations for Top 6 Infections 6. UTI Uncomplicated: Common E. coli, S. saprophyticus, other GNRs and enterococci Recommendation: Fluoroquinolones, bactrim, nitrofurantoin, amoxicillin or cephalosporin Complicated: Resistant GNR s, S. aureus, enterococci Recommendation : OUTPATIENT - fluoroquinolone, amox/clav, oral 3 rd gen ceph (cefpodoxime, cefdinir, ceftibuten) INPATIENT 3 rd gen ceph, fluoroquinolone, pip/tazo, carbapenem (not erta)

Things you should know about susceptibility testing. Brief (re)-introduction to primary classes of antibiotics Things to know and not test Intrinsic resistance patterns Don t go there Drug/site penetration discussion What doesn t belong?

When a doctor calls and asks

Will you release this drug?

When a doctor calls and asks YOU DOCTOR

Things to know and not test Organism Salmonella spp. Shigella spp. MRSA Enterococcus spp. Agents that Must not be reported as susceptible 1 st and 2 nd generation cephalosporins, cephamycins and aminoglycosides 1 st and 2 nd generation cephalosporins, cephamycins and aminoglycosides Penicillins, beta-lactam/beta-lactamase inhibitor combinations, cephalosporins** and carbapenems Aminoglycosides (except high concentrations), cephalosporins, clindamycin and trim/sulfa Location in CLSI M100-S21 Table 2A, Page 42 Table 2A, Page 42 Table 2C, Page 68 Table 2D, Page 84 ** Newer fifth generation cephalosporins (ceftobiprole and ceftaroline) have activity against MRSA WARNING: These antimicrobial agent/organism combinations may appear active in vitro but are not effective clinically and should be reported as susceptible

Other interesting intrinsic resistance characteristics Vancomycin Resistant Gram positives Enterococcus faecium Not intrinsically resistant but high percentage are VRE. Erysipelothrix Leuconostoc Pediococcus Lactobacillus Vancomycin Susceptible Gram negatives Chryseobacterium Sphingomonas Elizabethkingia

Other important intrinsic resistance characteristics GRAM NEGATIVES Stenotrophomonas maltophilia (metallo beta-lactamase) All beta-lactam antibiotics (except aztreonam) Klebsiella pneumoniae (class A betalactamase) Ampicillin Proteus mirabilis Nitrofurantoin Proteus vulgaris, Proteus penneri and Morganella Piperacillin, ampicillin cefoperazone (3 rd ), cefuroxime (2 nd ), cefazolin (1 st ) Pseudomonas aeruginosa Bactrim Burkholderia cepacia, Pandorea, Ralstonia pickettii, GC, Neisseria meningitidis, Moraxella catarrhalis, Brucella, Proteus, Providencia and Serratia Colistin Aeromonas Ampicillin Achromobacter spp. Aminoglycosides

Drug-Site Contraindications: Should not be routinely reported for bacteria isolated from these sites Oral agents CSF 1 st and 2 nd generation cephalosporins (except cefuroxime) Cephamycins Clindamycin Macrolides Tetracyclines Fluoroquinolones Respiratory Daptomycin Urine Macrolides

Good resources Medical letter - http://www.medicalletter.org/downloads/t94-1.pdf Sanford Guide CLSI document- M100 - Appendix Manual of Clinical Microbiology Antimicrobial Susceptibilities sections Clinical Microbiology Practices Handbook Section 5 procedure 5.16 http://labtestsonline.org

Glossary I and II Class, subclass, generic name Abbreviations / PO, IM, IV

Part 1 Part 2 CLSI M100-21 Page Glossary of Antimicrobial Agents

Questions?

Let s review: Salmonella from blood culture Drug Ampicillin Cefazolin Cefoxitin Cefotaxime Ciprofloxacin Gentamicin Interpretation Susceptible Susceptible Susceptible Susceptible Susceptible Susceptible What is wrong with this report? Cefazolin Cefoxitin Gentamicin

Let s review: MRSA from blood culture Drug Penicillin Cefazolin Oxacillin Meropenem Vancomycin Clindamycin Bactrim Interpretation Resistant Resistant Resistant Susceptible Susceptible Susceptible Susceptible What is wrong with this report? Meropenem

Let s review: Listeria monocytogenes from CSF Drug Ampicillin Gentamicin Cefotaxime Doxycline Clindamycin Interpretation Susceptible Susceptible Susceptible Susceptible Susceptible What is wrong with this report? Cefotaxime Doxycycline Clindamycin

Let s review: Enterococcus faecium from CSF Drug Ampicillin Gentamicin (High Level) Cefotaxime Bactrim Clindamycin Vancomycin Interpretation Resistant Susceptible Susceptible Susceptible Susceptible Resistat What is wrong with this report? Cefotaxime Clindamycin Bactrim

Let s review: ESBL producing Klebsiella pneumoniae from Urine Drug Ampicillin Cefazolin Cefalothin Gentamicin Cefotaxime Tigecycline Ciprofloxacin Cefepime Meropenem Clindamycin Interpretation Resistant Resistant Resistant Resistant Resistant Susceptible Resistant Resistant Resistant Susceptible What is wrong with this report? Meropenem Clindamycin